Page results
-
UCLH Charity is delighted to announce that the Dangoor Family’s Exilarch’s Foundation has pledged a £1.2m gift to support the next phase of the development of the CAR T programme at University College London Hospitals NHS Foundation Trust (UCLH). The CAR T Speed Release Project aims to reduce the time between extracting patient’s stem cells and injecting re-engineered CAR T cells back into patients with cancer to fight cancer cells.
-
Patient information for Red Cell Network patients
-
Education and training videos for Red Cell Network patients
-
A national study with initial results shows steroid dexamethasone may substantially reduce mortality in severely ill Covid-19 patients.
-
The Sickle Cell Society (SCS) and the UK Thalassaemia Society (UKTS) have worked in partnership with the NHS sickle cell and thalassaemia (SCT) screening programme to engage with communities less likely to access health information through usual NHS channels. The societies provide feedback from people that share the same population background or have experience of the condition and to feed into the programme updates and improvements.
-
An immunotherapy drug given before surgery instead of chemotherapy meant that significantly more patients with a certain genetic profile were cancer free after surgery, according to clinical trial results presented by researchers at UCL and UCLH.
-
Bladder cancer is where a growth of abnormal tissue, known as a tumour, develops in the bladder lining. In some cases, the tumour spreads into the surrounding areas.
-
Participants reacted quicker and made fewer errors during menstruation, despite believing their performance would be worse, according to new research from UCL and the Institute of Sport, Exercise & Health (ISEH).
-
Medtronic are discontinuing the MiniMed™ Mio™ Infusion sets. If you are currently using MiniMed™ Mio™ infusion sets, you will need to change to an alternative infusion set before 31 March 2023. After this date, MiniMed™ Mio™ infusion sets will no longer be available.
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
File results
-
FOI/2024/0450 - Trust-wide obesity and weight management strategy
-
FOI/2024/0440 - Patient reported outcome measures (PROMs) in oncology
-
FOI/2024/0439 - Digital dictation provider
-
FOI/2024/0438 - IT electronic signature software service/ e-Signatures
-
FOI/2024/0431 - Hospital patient monitoring system on wards
-
FOI/2024/0428 - Physiotherapy/ occupational recruitment for 2023
-
FOI/2024/0426 - Agency staff spend for nursing, HCAs, pharmacists, occupational therapists and physiotherapists
-
FOI/2024/0425 - Freedom of Information (FOI) structure, banding and job titles
-
FOI/2024/0423 - Giant cell arteritis (GCA) patient treatment
-
FOI/2024/0402 - Various IT systems used at the Trust